Gracell Biotechnologies Inc.

Market Cap

$990M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$629.20+$244.20 (+63.43%)

Jul 15, 2026

52W High $629.2052W Low $306.85

Company Details

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-e...

Leadership

Wei Cao BM, Ph.D.Founder

Founder, Chairman & CEO

Yili Xie M.B.A., Ph.D.

Chief Financial Officer

Samuel Suhua Zhang M.B.A., Ph.D.

Chief Business Officer

Wendy Li M.D.

Chief Medical Officer

Erin Li

Executive Officer

IPO Date

Jan 8, 2021

Website

www.gracellbio.com

Key Metrics TTM (CNY)

Revenue

¥0

- YoY

Net Income

-¥497M

EPS (Diluted)

Free Cash Flow

Revenue / Share

¥0.00

Gross Margin

Operating Margin

Net Margin

FCF Margin

P/S

P/E

Revenue & Profitability (CNY)

Operating Cash Flow (CNY)

CapEx Spend (CNY)

CapEx Spend

OpEx vs Revenue Growth (YoY)

OpEx Breakdown (CNY)

War Chest (CNY)

Shares Outstanding